Formulation and Evaluation of Vincristine Sulfate By Mucosal Drug Delivery for Advanced Chemotherapy
Keywords:
Vincristine sulfate, Mucosal drug delivery, Cytotoxicity, In vitro assays, Antioxidant activity, Apoptosis, Cancer therapeutics, Bioavailability, Drug formulationAbstract
The present study focuses on the formulation and evaluation of a Vincristine sulfate delivery system intended for mucosal administration to enhance therapeutic efficacy and minimize systemic toxicity. The research aims to design, characterize, and assess the cytotoxic effects of the developed formulation on normal human cell lines using a series of in vitro assays. Cell viability, proliferation, and apoptosis were evaluated through MTT, Trypan Blue exclusion, and Propidium Iodide staining assays to determine dose-dependent cytotoxic responses.
In addition, the antioxidant potential of the formulation was examined to explore its protective and therapeutic implications. Comparative analysis with conventional Vincristine sulfate delivery methods was performed to assess improvements in bioavailability and therapeutic index. The results are expected to provide insights into the formulation’s mechanism of action, safety profile, and overall efficacy. By addressing the limitations of traditional delivery routes, this mucosal Vincristine sulfate formulation represents a promising approach for enhancing cancer treatment outcomes. The findings of this research contribute to the broader understanding of Vincristine sulfate’s pharmacological potential and support the development of more effective and safer drug delivery strategies for oncology applications
Downloads
References
World Health Organization. Cancer Fact Sheet. [Internet]. Available from: [WHO Website].
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674.
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789-799.
World Health Organization. WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All. 2020. Licence: CC BY-NC-SA 3.0 IGO.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Weinberg RA. The Biology of Cancer. 2nd ed. New York: Garland Science; 2013.
Creighton CJ. Making use of cancer genomic databases. Curr Protoc Mol Biol.2018;121:13-19.
Yang Y, Dong X, Xie B, et al. Databases and web tools for cancer genomics study. Dev Reprod Biol. 2015;13(1):46-50.
Hinkson IV, Madej B, Stahlberg EA. Accelerating therapeutics for opportunities in medicine: A paradigm shift in drug discovery. Front Pharmacol.2020;11:770.
Keenan AB, Wojciechowicz ML, Wang Z, et al. Connectivity mapping: methods and applications. Annu Rev Biomed Data Sci.2019;2:69-92.
Mulder NJ, Adebiyi E, Adebiyi M, et al. Development of bioinformatics infrastructure for genomics research. Global Heart. 2017;12(2):91-98.
Friedmann-Morvinski D, Verma IM. Dedifferentiation and reprogramming: Origins of cancer stem cells. EMBO Rep. 2014;15(3):244-253.
Schwartzman O, Tanay A. Single-cell epigenomics: techniques and emerging applications. Nat Rev Genet. 2015;16(12):716-726.
Verma M. Genome-wide association studies and epigenome-wide association studies go together in cancer control. Future Oncol. 2016;12(13):1645-1664.
Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: The potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79.
Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer. 2007;5(7):422-426.
Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra-terminal motif inhibitors: A review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):FSO372..
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
